日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05)

培美曲塞维持治疗与观察治疗在完成一线铂类化疗且未出现疾病进展的晚期尿路上皮癌患者中的疗效比较（PREMIER，KCSG GU16-05）

期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2024.1003
Park, Inkeun; Yoon, Shinkyo; Kim, Ilhwan; Park, Kwonoh; Lee, Suee; Keam, Bhumsuk; Park, Joo-Hwan; Kim, Jin Young; Choi, Yoon Ji; Sohn, Byeong Seok; Lee, Jae Lyun
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

针对 EGFR 或 ALK 突变型非小细胞肺癌患者的阿特珠单抗联合贝伐珠单抗和化疗的 III 期随机研究 (ATTLAS, KCSG-LU19-04)

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.23.01891
Park, Sehhoon; Kim, Tae Min; Han, Ji-Youn; Lee, Gyeong-Won; Shim, Byoung Yong; Lee, Yun-Gyoo; Kim, Sang-We; Kim, Il Hwan; Lee, Suee; Kim, Yu Jung; Park, Ji Hyun; Park, Sang-Gon; Lee, Ki Hyeong; Kang, Eun Joo; Kim, Ju Won; Shin, Seong-Hoon; Ock, Chan-Young; Nam, Byung-Ho; Lee, Jaebong; Jung, Hyun-Ae; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Ahn, Myung-Ju
肺癌
肿瘤
肿瘤免疫
ALK
EGF
EGFR
细胞生物学
发表日期：2024
文献求助 收藏

Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors

免疫检查点抑制剂治疗患者免疫细胞组分的变化

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers14143440
Kim, Hye Ryeon; Kang, Jung Hun; Kim, Sung Hyun; Kim, Seung Tae; Kim, Ilhwan; Min, Young Joo; Shin, Seong Hoon; Oh, Sung Yong; Lee, Gyeong-Won; Lee, Ji Hyun; Ji, Jun Ho; Huh, Seok Jae; Lee, Suee
Checkpoint
细胞生物学
免疫/内分泌
发表日期：2022
文献求助 收藏

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities

表皮生长因子软膏治疗表皮生长因子受体抑制剂引起的皮肤毒性的随机对照试验

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2019-0221
Kim, Young Saing; Ji, Jun Ho; Oh, Sung Yong; Lee, Suee; Huh, Seok Jae; Lee, Ji Hyun; Song, Ki-Hoon; Son, Choon Hee; Roh, Mee Sook; Lee, Gyeong Won; Lee, Jeeyun; Kim, Seung Tae; Kim, Chan Kyu; Jang, Joung Soon; Hwang, In Gyu; Ahn, Hee Kyung; Park, Lee Chun; Oh, So Yeon; Kim, Seong-Geun; Lee, Sang-Cheol; Lim, Do-Hyoung; Lee, Soon Il; Kang, Jung Hun
信号转导
毒理研究
发表日期：2020
文献求助 收藏

Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea

韩国308例透明细胞卵巢癌患者的回顾性多中心研究：临床特征

期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2019.292
Lee, Hee Yeon; Hong, Ji Hyung; Byun, Jae Ho; Kim, Hee-Jun; Baek, Sun Kyung; Kim, Jin Young; Kim, Ki Hyang; Yun, Jina; Kim, Jung A; Park, Kwonoh; Lee, Hyo Jin; Lee, Jung Lim; Won, Young-Woong; Kim, Il Hwan; Bae, Woo Kyun; Park, Kyong Hwa; Sun, Der-Sheng; Lee, Suee; Lee, Min-Young; Lee, Guk Jin; Hong, Sook Hee; Jung, Yun Hwa; An, Ho Jung
细胞生物学
肿瘤
肿瘤免疫
卵巢癌
发表日期：2020
文献求助 收藏

Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing

使用下一代测序对结外边缘区淋巴瘤进行突变分析

期刊:Oncology Letters
影响因子:2.5
doi:10.3892/ol.2020.12068
Seok Jae Huh, Sung Yong Oh, Suee Lee, Ji Hyun Lee, Sung Hyun Kim, Min Kyung Pak, Hyo-Jin Kim
肿瘤
淋巴瘤
发表日期：2020
文献求助 收藏

rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects

rhEGF 治疗可改善 EGFR 抑制剂引起的皮肤屏障和免疫缺陷

期刊:Cancers
影响因子:
doi:10.3390/cancers12113120
Ji Min Kim, Jun Ho Ji, Young Saing Kim, Suee Lee, Sung Yong Oh, Seok Jae Huh, Choon Hee Son, Jung Hun Kang, So Yun Ahn, Jung Eun Choo, Ki-Hoon Song, Mee Sook Roh
免疫
发表日期：2020
文献求助 收藏

Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

R-CVP 方案序贯利妥昔单抗维持治疗晚期边缘区淋巴瘤患者的 II 期研究：淋巴瘤生存改善联盟 (CISL) 研究

期刊:Cancer Communications
影响因子:24.9
doi:10.1186/s40880-019-0403-7
Oh, Sung Yong; Kim, Won Seog; Kim, Jin Seok; Kim, Seok Jin; Yoon, Dok Hyun; Yang, Deok-Hwan; Lee, Won Sik; Kim, Hyo Jung; Yhim, Ho-Young; Jeong, Seong Hyun; Won, Jong Ho; Lee, Suee; Kong, Jee Hyun; Lim, Sung-Nam; Ji, Jun Ho; Kwon, Kyung A; Lee, Gyeong-Won; Lee, Jae Hoon; Lee, Ho Sup; Shin, Ho-Jin; Suh, Cheolwon
淋巴瘤
发表日期：2019
文献求助 收藏

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)

伊立替康联合卡培他滨与卡培他滨单药治疗既往接受过蒽环类和紫杉烷类药物治疗的转移性乳腺癌患者的随机开放标签 III 期试验：PROCEED 试验 (KCSG BR 11-01)

期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2017.562
Park, In Hae; Im, Seock-Ah; Jung, Kyung Hae; Sohn, Joo Hyuk; Park, Yeon Hee; Lee, Keun Seok; Sim, Sung Hoon; Park, Kyong-Hwa; Kim, Jee Hyun; Nam, Byung Ho; Kim, Hee-Jun; Kim, Tae-Yong; Lee, Kyung-Hun; Kim, Sung-Bae; Ahn, Jin-Hee; Lee, Suee; Ro, Jungsil
肿瘤
肿瘤免疫
乳腺癌
EED
发表日期：2019
文献求助 收藏

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

BioPATH：一项针对接受拉帕替尼和其他抗HER2疗法治疗的HER2阳性晚期乳腺癌亚洲患者的生物标志物研究

期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2018.598
Kim, Sung-Bae; Do, In-Gu; Tsang, Janice; Kim, Tae-You; Yap, Yoon-Sim; Cornelio, Gerardo; Gong, Gyungyub; Paik, Soonmyung; Lee, Suee; Ng, Ting-Ying; Park, Sarah; Oh, Ho-Suk; Chiu, Joanne; Sohn, Joohyuk; Lee, Moonhee; Choi, Young-Jin; Lee, Eun Mi; Park, Kyong-Hwa; Nathaniel, Christos; Ro, Jungsil
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2019
文献求助 收藏